Armstrong Fleming & Moore’s Novo Nordisk NVO Stock Holding History

Armstrong Fleming & Moore’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,878	Closed	-$299K	–	111
2025 Q4	$299K	Sell	5,878 -234	-4%	-$12K	0.14%	77
2025 Q3	$339K	Buy	6,112 +806	+15%	+$47.2K	0.16%	79
2025 Q2	$366K	Buy	+5,306	New	+$361K	0.2%	69
2025 Q1	–	Sell	-5,924	Closed	-$510K	–	135
2024 Q4	$510K	Sell	5,924 -1,608	-21%	-$174K	0.31%	55
2024 Q3	$897K	Buy	7,532 +500	+7%	+$66.7K	0.52%	38
2024 Q2	$1M	Buy	7,032 +2,374	+51%	+$315K	0.64%	28
2024 Q1	$598K	Hold	4,658	–	–	0.41%	46
2023 Q4	$482K	Hold	4,658	–	–	0.36%	54
2023 Q3	$424K	Buy	4,658 +330	+8%	+$29.1K	0.41%	54
2023 Q2	$350K	Buy	+4,328	New	+$354K	0.32%	63

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Armstrong Fleming & Moore's NVO Position: Q1 2026 in Review

Armstrong Fleming & Moore sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 5,878 shares — an estimated $299K sold.

Armstrong Fleming & Moore first reported a position in NVO in Q2 2023 and held it in 10 quarters. The position peaked at $1M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Armstrong Fleming & Moore reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Armstrong Fleming & Moore sold 5,878 Novo Nordisk shares in Q1 2026, an estimated $299K.
Armstrong Fleming & Moore first reported a position in Novo Nordisk in Q2 2023 and held it in 10 quarters.
Armstrong Fleming & Moore's Novo Nordisk position peaked at $1M in Q2 2024.
1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Armstrong Fleming & Moore's 13F filing for Q1 2026, filed 13 Apr 2026.